Global Ganja Report

As evidence mounts for the efficacy of cannabis in treating PTSD, medical marijuana is fast being normalized in the veterans' community. But many have been "exiled" from their home states that have no medical marijuana programs—and the federal Department of Veterans Affairs is only beginning to demonstrate any tolerance on the question.

With general legalization in Oregon, the number of people enrolled in the state medical marijuana program is plummeting, and there is talk of actually ending it. Authorities have already dramatically slashed the limit for daily sales, supposedly in a crackdown on diversion to the black market—which continues to thrive, even amid the notorious over-supply.

The push to legalize cannabis in the Empire State got a significant boost on Election Day as Democrats took control of the state Senate—long controlled by Republicans. A re-elected Gov. Cuomo played to a progressive base on the campaign trail, and will no longer be able to blame GOP intransigence for lack of progress. Will New York become the 11th state to legalize in 2019?

Cannabis is set to become legal in Michigan after voters in the Wolverine State passed Proposal 1 during the midterm elections. 

The passage of Prop 1 makes Michigan the 10th state in the nation and the first in the Midwest to legalize cannabis for "recreational" use, joining California, Oregon, Washington, Alaska, Colorado, Nevada, Massachusetts, Vermont, Maine and Washington DC.

Voters in several states will cast ballots on cannabis-related measures in the Nov. 6 midterm election. Michigan and North Dakota are facing general legalization measures, while Utah and Missouri voters will get to weigh in on medical marijuana.

A major player in Canada's legal cannabis sector is seeking to acquire a troubled US-based company—the latest example of the trend toward consolidation in the industry now crossing international borders.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.